Clinical Trial Update: Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Pembrolizumab plus Lenalidomide after autologous stem cell transplant in high-risk multiple myeloma was terminated; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2023-08-22